Screener
Monopar Therapeutics MNPR Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
| Line item | March 31, 2026 | December 31, 2025* |
|---|---|---|
| Total liabilities | 2,589,313 | 2,890,156 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Common stock, par value of $0.001 per share, 40,000,000 shares authorized, 6,699,062 and 6,692,140 shares issued and outstanding at March 31, 2026, and December 31, 2025, respectively | 6,699 | 6,692 |
| Additional paid-in capital | 228,691,772 | 227,199,002 |
| Accumulated other comprehensive income (loss) | 98,521 | 131,389 |
| Retained earnings (accumulated deficit) | (93,402,580) | (89,509,530) |
| Total stockholders’ equity | 135,394,412 | 137,827,553 |
Document
FAQ
- What is Monopar Therapeutics's common stock?
- Monopar Therapeutics (MNPR) reported common stock of $6.7K in Q1 2026.
- How has Monopar Therapeutics's common stock changed year-over-year?
- Monopar Therapeutics's common stock increased by 9.6% year-over-year, from $6.12K to $6.7K.
- What is the long-term trend for Monopar Therapeutics's common stock?
- Over 5 years (2020 to 2025), Monopar Therapeutics's common stock has grown at a -10.2% compound annual growth rate (CAGR), from $11.45K to $6.69K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Monopar Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude